Trial Profile
Phase IV Study on New Insights in Remodeling of Diabetic Cardiomyopathy: Gender Difference in Intramyocardial, Molecular and Neuroendocrine Assessment in Response to Chronic Inhibition of Cyclic GMP Phosphodiesterase 5A
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Tadalafil (Primary)
- Indications Diabetic cardiomyopathy; Type 2 diabetes mellitus
- Focus Biomarker; Therapeutic Use
- Acronyms RECOGITO
- 09 Jul 2019 Status changed from recruiting to completed.
- 27 Jan 2018 Planned End Date changed from 1 Mar 2018 to 1 Jan 2019.
- 11 Mar 2013 New trial record